TG Therapeutics, Inc. (TGTX) Given “Buy” Rating at HC Wainwright
TG Therapeutics, Inc. (NASDAQ:TGTX)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday, StockTargetPrices.com reports. They currently have a $33.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 300.00% from the stock’s current price.
Several other brokerages have also commented on TGTX. ValuEngine lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Zacks Investment Research lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 12th. BidaskClub upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 24th. Finally, SunTrust Banks, Inc. restated a “buy” rating and issued a $28.00 price objective on shares of TG Therapeutics in a report on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $26.78.
Shares of TG Therapeutics (NASDAQ TGTX) opened at $8.25 on Tuesday. TG Therapeutics has a 1-year low of $4.10 and a 1-year high of $15.35.
Institutional investors have recently modified their holdings of the stock. Legal & General Group Plc increased its stake in shares of TG Therapeutics by 4.1% in the 1st quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 384 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in TG Therapeutics during the 2nd quarter valued at about $156,000. Bank of America Corp DE grew its position in TG Therapeutics by 11.0% during the 1st quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 1,395 shares during the last quarter. HighTower Advisors LLC purchased a new stake in TG Therapeutics during the 1st quarter valued at about $170,000. Finally, BB&T Securities LLC grew its position in TG Therapeutics by 63.0% during the 2nd quarter. BB&T Securities LLC now owns 16,949 shares of the biopharmaceutical company’s stock valued at $170,000 after purchasing an additional 6,549 shares during the last quarter. Institutional investors own 49.58% of the company’s stock.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.